Ikarian Capital, LLC Next Cure, Inc. Transaction History

Ikarian Capital, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	SELL	$3.38 - $5.27 $235,325 - $366,913	-69,623 Reduced 49.36%	71,435 $336,000
Q1 2022 May 13, 2022	BUY	$4.76 - $6.24 $33,334 - $43,698	7,003 Added 5.22%	141,058 $686,000
Q4 2021 Feb 14, 2022	SELL	$5.7 - $9.1 $2.14 Million - $3.41 Million	-375,100 Reduced 73.67%	134,055 $804,000
Q3 2021 Nov 15, 2021	SELL	$6.74 - $8.02 $51,999 - $61,874	-7,715 Reduced 1.49%	509,155 $3.43 Million
Q2 2021 Aug 16, 2021	BUY	$7.6 - $10.28 $478,176 - $646,797	62,918 Added 13.86%	516,870 $4.15 Million
Q1 2021 May 17, 2021	BUY	$9.81 - $13.88 $2.49 Million - $3.52 Million	253,952 Added 126.98%	453,952 $4.54 Million
Q3 2020 Nov 16, 2020	BUY	$8.15 - $21.17 $1.63 Million - $4.23 Million	200,000 New	200,000 $1.76 Million

15.9M

Ticker NXTC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 27,748,800
Market Cap $36.4M
Description
NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The comp...

Get notified when there are updates to the investment portfolio of Ikarian Capital, LLC, based on Form 13F filings with the SEC.

Stay updated on Ikarian Capital, LLC with notifications on news.